About us

As a major player in the field of oncology in the Ile-de-France region, the Cancer Institute AP-HP. Nord – Université Paris Cité brings together the hemato-oncological care, research, and education activities of seven hospitals, all located in the north of Paris and making up the university hospital group AP-HP. Nord – Université Paris Cité, along with the Université Paris Cité.

The Cancer Institute develops reference activities in bone marrow transplantation, cell therapies (CAR-T), immunotherapy, and early-phase clinical trials, to provide patients with the highest level of care and to achieve excellence in cancer research. It promotes the pooling of knowledge, skills, and resources between hospitals.

Hôpital Beaujon
Hôpital Bichat
Claude-Bernard
Hôpital
Bretonneau
Hôpital Lariboisière
Fernand-Widal
Hôpital
Louis-Mourier
Hôpital
Robert-Debré
Hôpital
Saint-Louis

The university hospital group AP-HP. Nord – Université Paris Cité, founded on July 1, 2019, encompasses the AP-HP university hospitals located in the northern part of Paris: BeaujonBichat – Claude-BernardBretonneauLariboisière – Fernand-WidalLouis-MourierRobert-DebréSaint-Louis.

It represents one of the largest hospital complexes of the AP-HP, with more than 3,900 beds, 300,000 hospital stays, 1,300,000 consultations, and 460,000 emergency room visits in 2019–2020.

More than 19,000 professionals work there, of whom 15,000 are paramedical, administrative, logistical, and technical professionals, and 4,000 are senior internal and external physicians. The budget for this new entity represents 1.7 billion euros.

Europe’s leading hospital and university center, the AP-HP and its 38 hospitals are organized into six university hospital groups and are articulated around five universities in the Ile-de-France region. Closely linked to major research organizations, the AP-HP has eight world-class university hospital institutes and the largest  french data warehouse in health

Read more…

As a university conducting intensive multidisciplinary research and awarded the « Initiative of Excellence » label, Université Paris Cité has reached the highest international level thanks to its research, the diversity of its training programs, its support to innovation, and its active contribution to the construction of the European research and training area.

Read more…

A QUICK PIECE OF HISTORY

The Cancer Institute AP-HP. Nord – Université Paris Cité draws on the legacy of Professor Jean Dausset, a Nobel Prize winner in medicine who practiced at the Saint-Louis hospital and whose in-depth knowledge of the major histocompatibility complex (MHC) facilitated the development of bone marrow allografts for the treatment of hematological malignancies at the end of the 20th century.

ONE INSTITUTE, ONE UNIVERSITY, SEVEN HOSPITALS

As a major player in the field of oncology in the Ile-de-France region, the Cancer Institute AP-HP. Nord – Université Paris Cité brings together the hemato-oncological care, research, and education activities of seven hospitals, all located in the north of Paris and making up the university hospital group AP-HP. Nord – Université Paris Cité, along with the Université Paris Cité.

carte institut cancer 2023

OUR MISSIONS, OUR AMBITION

The Cancer Institute AP-HP. Nord – Université Paris Cité pools the strengths of the Saint-Louis, Bichat – Claude-Bernard, Beaujon, Robert-Debré, Lariboisière, Louis-Mourier, and Bretonneau hospitals in all areas of oncology, developing reference activities in bone marrow transplantation, cell therapies (CAR-T), and early-phase clinical trials, in order to provide patients with the highest level of care and to achieve excellence in cancer research.

More than 150 physicians, 180 researchers, engineers and post-doctoral fellows are engaged in cancer treatment as well as basic and translational research activities.

The objective of the Cancer Institute AP-HP. Nord – Université Paris Cité is to structure this network of hospitals into a single university hospital entity.

Dedicated to coordinated patient care and cancer research, with coherent and clear pathways offered to patients, the Institute promotes the pooling of
knowledge, skills, and resources between the hospitals involved in cancer care, research, and teaching.

OUR CARE OFFER

A comprehensive cancer care offer, from childhood to old age

  • Highly structured medico-surgical organ oncology: digestive system, thorax, ENT, urology, senology-gynecology, dermatology, neurology
  • Hematology of international outreach, a cutting-edge know-how with Car-T cells, unique in the AP-HP, and bone marrow allograft
  • Medical oncology and radiotherapy: support care, pain, and oncogenetics
  • Radiotherapy: RadiomiX, stereotaxis, vectorized radiotherapy
  • Immunotherapy, targeted therapy, nuclear imaging, early-phase trials
  • Biobank, tumor genomics, research
  • Rare cancers and rare hemopathies
  • Structured oncogeriatrics

6 rapid diagnostic cancer centers

  • Liver, biliary ducts, Beaujon hospital
  • Hematology, Saint-Louis hospital
  • Lung nodules, Bichat – Claude-Bernard hospital
  • Pancreas, Beaujon hospital
  • Breast, Saint-Louis hospital
  • Neuroendocrine tumors, Beaujon hospital

Professor Gérard Zalcman, Medical Director of the Cancer Institute

Prof. Gérard Zalcman focuses his research activities on clinical research in thoracic oncology, as the principal investigator of large phase III trials promoted by the French Intergroup of Thoracic Cancerology (IFCT) which he chaired for four years.

He is a professor of pneumology at the Université Paris Cité and heads the department of thoracic oncology at the Bichat – Claude-Bernard hospital. As a member of the INSERM Unit 830 « Cancer, Heterogeneity and Plasticity », at the Institut Curie Research Center, he co-leads a team developing new microfluidic devices for cell biology, so-called « cancer-on-chips », dedicated to the study of the cancer microenvironment.

He has been appointed Medical Director of the Cancer Institute AP-HP. North – Université Paris Cité in 2020.

Professor Céleste Lebbé, Deputy Medical Director of the Cancer Institute

Prof. Céleste Lebbé is a professor of dermatology at the Université Paris Cité, head of the skin cancer center at the Saint-Louis hospital, member of the Saint-Louis Research Institute, Inserm Unit U976 HIPI (Human Immunology, Pathophysiology, Immunotherapy), very involved in clinical and translational research on melanoma and viral-induced skin cancers.

She has been appointed Deputy Medical Director of the Cancer Institute AP-HP. North – Université Paris Cité.

KEY FIGURES (2022)

The Cancer Institute AP-HP. Nord – Université Paris Cité has embarked on a process of accreditation as a Comprehensive Cancer Center by the OECI (Organisation of European Cancer Institutes).

Granted for 5 years, this accreditation is the result of an ongoing process that is part of the institutional project of the AP-HP. Nord – Université Paris Cité university hospital group. It aims to structure patient care at all stages of the care pathway and access to research and innovation.

OECI audit from june 24 to june 26, 2024

To increase the quality

of care, research, and care-research interactions

To structure the cancer dimension

within the AP-HP Nord – Université Paris Cité

To increase our visibility

national and international visibility in a competitive field

To participate in a European network

capable of responding as a center to calls for tender

The Cancer Patients Committee of the Institute brings together representatives from the main patient associations dealing with cancer or malignant hematological disorders, active within the GHU AP-HP Nord – Université Paris Cité. It closely interfaces with the Hospital Users Committees as well as with the Patient Engagement Committee of the GHU.

Patient empowerment : the involvement and power of the patient

Patient commitment is the keystone of our quality approach and is based on a reciprocal commitment:

  • from the patient, who shares with the hospital team feedback on his or her experience
  • from our teams to the patients for a common goal and mutual benefits.

The impact on the improvement of the quality and safety of patient care goes hand in hand with an improvement in the quality of life and job satisfaction of the hospital teams. Patient participation, with the patient being her/his key managerial actor, is being promoted, thus becoming an integral part of our daily practices and projects.

Setting up a Cancer Patients Committee at the Cancer Institute AP-HP. Nord - Université Paris Cité

A « Cancer Patients Committee » has been created in June 2023, in accordance with the DHOS circular n° 2004-516 from October 28, 2004 and OECI standard N°19, which relate to patients’ committees within health institutions providing cancer treatment.

This committee gathers members of the main associations of patients with cancer or hematological malignancies, which are active within the GHU. The committee works in close link with the user commissions of the hospitals, the GHU, and the GHU’s patient commitment committee.

The main goals of the Cancer Patients Committee are to:

Raise awareness among hospital and translational research teams

about patients' needs for information on cancer and its management, as well as on clinical cancer research

Promote dialogue among patients, hospital teams, and cancer research teams

but also include patients into clinical or translational cancer research protocol development to enable a better understanding and adherence by the patients

Improve the everyday life of patients treated in the cancer services of the GHU AP-HP. Nord

by collaborating with the authorities, CMEL and coordination team of the Cancer Institute, in order to provide feedbacks on the care, organization, and how hospitals work in cancerology

Participate in the general assemblies of the "Cancer Institute" Federation

and in the "Medical, Paramedical, Ethics and PROMs" thematic axis meetings of the Cancer Institute, by being a force of proposal

Review and provide a feedback on all information documents

intended for patients, provided by all clinical and research structures of the Cancer Institute

Supply any ethical opinion that its members may want to spontaneously issue

or when requested by the GHU components, especially concerning clinical and translational research protocols promoted within the GHU and the SIRIC, as well as on information documents given to patients, or proposing patient’s to participate, by evaluating if these documents are clear and understandable to all

Cancer Patients Committee’s members

Associations

Association pour le cancer du poumon

Association pour le cancer du poumon avec translocations ALK ou ROS

Réseau social pour les personnes atteintes d’un cancer du poumon

Association pour le cancer de la prostate

Association pour le cancer du pancréas

Association pour le cancer du sein

Association pour différents cancers

Association nationale de défense des victimes de l’amiante

Association pour la leucémie

Association pour les myélodysplasies

Association pour les hémopathies malignes

Association pour les cancers pédiatriques

Association pour la néoplasie myéloproliférative

Réseaux sociaux privés pour les patients et leurs proches

Forums de discussion pour la thyroïde

Association pour les tumeurs endocrines diverses

Association pour les patients sous traitement anticoagulant

Association pour aider les patients à surmonter la maladie par l’art et la danse

Comité de Paris de la Ligue contre le Cancer

Cancer Patients Committee Office

Karin Tourmente
Vivre avec une NMP
Marie Dautel
Anticoag-pass-S2D
Geneviève Alberti
Ligue contre le Cancer
Flora Sandoval
Mon réseau Cancer du Sein
Adbelhalim El Gaddari
ALK-ROS

General Assembly Representatives

Flora Sandoval
Geneviève Alberti
Karin Tourmente

3Cs representatives

Marie Dautel
East 3C
Christine Rodien-Louw
West 3C
Geneviève Alberti
Pediatric 3C

SIRIC Representative

Geneviève Alberti

A MAJOR ASSET, OUR RESEARCH

The Cancer Institute AP-HP. Nord – Université Paris Cité brings together 13 fundamental research teams and 25 clinical and translational research teams which implement a rich research activity fundamental and transfer in oncology.

Their work is dedicated to hematological malignancies, cell therapy (Saint-Louis Research Institute), and solid cancers (Saint-Louis Research Institute, Inflammation Research Center, CIC 1427 and 1425), with the rise of targeted therapies and immunotherapy, based on the use of genomic biomarkers, cell biology platforms, biobanks and innovative imaging techniques.

Research : key figures (2022)

Our research is:

  • A hemato-oncology and biotherapy research institute at the SaintLouis hospital with five EA/ EPST (reception team/primary, secondary and technical education) units and 23 teams + platforms (cytometry, genomics, microscopy, bioData center)
  • A SIRIC InSiTu
  • A SIRIC Paris Kids Cancer
  • A population genetics Institute, historical partner (CEPH) founded by Nobel Prize winner in Medicine Jean Dausset.
  • Two innovative FHU (university hospital federations): APOLLO (fibrosis and lung cancer), MOSAIC (multimodal imaging, from biology to magnetic resonance imaging [MRI] and an artificial intelligence applied to cancerology).
  • An IHU (university hospital institute): THEMA 2
  • Two RHU (university hospital research in health) SPRINT and Liver-Track.
  • An inflammation research center (the CRI) at the Bichat Claude-Bernard and Beaujon hospitals with a strong research focus on «cancer inflammation».
  • Accredited early-phase trial centers: CIC Saint-Louis, CIC Bichat forming the CLIP2 Paris-Nord.
  • A long-standing involvement in cancer cooperative groups (GCO): LYSA, FFCD, IFCT, GFELC, GCC, GETUG.
  • Rare tumor expert centers with INCa (French national cancer institute) accreditation: onco-dermatology (Gefelc, CARADERM), mesotheliomas (Net-meso), sarcomas (NetSarc), NE digestive tumors (Renaten), HIV cancer, K-virogref, TUTHYREF.

CLINICAL TRIALS

At the Cancer Institute AP-HP. Nord – Université Paris Cité, many clinical trials are open to inclusion.

Are you a patient?

Your doctor will explain whether your pathology makes you eligible for a trial.

Are you a doctor?

Do you have a patient eligible for one of these trials? We invite you to contact the person indicated for each trial.

Find out about clinical trials open to inclusion: